Sanofi

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sanofi inks an agreement with Orano Med to develop next-generation radioligand medicines to treat rare cancers.

SNY Inks Deal With Orano Med for Next-Generation Radioligand Therapies

French private equity firm PAI Partners has submitted a new, higher offer for Sanofi's consumer health business Opella, the Le Monde newspaper said on Thursday, as PAI seeks to outbid U.S. rival Clayton Dubilier & Rice (CD&R).

PAI Partners makes higher offer for Sanofi's Opella, says Le Monde

Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, October 17, 2024. Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines.

Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines

US FLUBLOK label1 updated to incorporate new safety study in pregnant individuals New safety data involving more than 48,000 pregnant individuals published in American Journal of Obstetrics and Gynecology (AJOG) Global Reports Recombinant or inactivated flu vaccines are recommended by the U.S. Centers for Disease Control and Protection (CDC), Advisory Committee on Immunization Practices (ACIP) and American College of Obstetricians and Gynecologists (ACOG) for individuals who are or will become pregnant during flu season2,3,4 Sanofi is committed to the ongoing rigorous scientific study of flu vaccines in at-risk populations, including older patients, patients with comorbidities and pregnant individuals BRIDGEWATER, N.J. , Oct. 16, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has updated the label for FLUBLOK (Influenza Vaccine) to include data from a new safety study involving pregnant individuals 18 years and older, in time to inform those hoping to comply with U.S. Centers for Disease Control and Prevention (CDC) recommendations to receive their annual flu vaccine ideally before the end of October.4 ,5 The results from the study of more than 48,000 pregnant individuals across multiple flu seasons were recently published in American Journal of Obstetricians and Gynecologists (AJOG) Global Reports and demonstrate FLUBLOK safety is consistent with a standard-dose flu vaccine and pregnancy-related outcomes in the general population.1 , 5 Thomas Grenier Head of Vaccines, North America, Sanofi "Today, we're proud to announce an important update to our label for FLUBLOK, from one of Sanofi's largest flu vaccine safety studies ever done in pregnant individuals, an important at-risk population group for influenza.

FLUBLOK® (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals

Sanofi is in discussions with the French government to address concerns officials raised about a potential sale of a controlling stake in the company's consumer health business, Opella, to private-equity firm Clayton Dubilier & Rice.

Sanofi in Talks With French Government to Address Concerns on Opella Deal

France's CGT and CFDT unions have called on workers at pharma company Sanofi to strike from Thursday to show their protest against a planned sale of a controlling stake in the firm's consumer health arm, a union official said on Wednesday.

Workers at Sanofi to strike to protest consumer health unit sale, union official says

BRIDGEWATER, N.J. , Oct. 16, 2024 /PRNewswire/ -- Sanofi announced today it will contribute $18 million to three Historically Black Medical Schools to help the institutions work to increase diversity in clinical studies.

Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies

France is considering taking a stake in Sanofi's Opella arm, said finance minister Antoine Armand, to allay concerns that the French drugmaker's plans to sell a 50% stake in Opella to a U.S. private equity firm could result in job cuts.

France considering stake in Sanofi's Opella, minister says

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Sanofi (SNY) Stock?

The French government is seeking job guarantees from drugmaker Sanofi regarding its Doliprane production sites in the event of a sale of its consumer health branch, Economy Minister Antoine Armand said on Monday.

French government seeking job guarantees from Sanofi over Doliprane production sites

The French drugmaker said the negotiations are for a potential sale of a 50% controlling stake in Opella.

Sanofi in Talks to Sell Controlling Stake in Consumer Health Arm to CD&R

Sanofi on Friday said it's in talks with the private equity firm CD&R to sell just over half of its consumer healthcare business, in a deal that could yield billions of dollars for the French drugmaker.

Sanofi in talks to sell consumer healthcare business that makes Dulcolax

Sanofi has entered into discussions with U.S. private equity firm Clayton Dubilier & Rice to sell a controlling 50% stake in its consumer health business Opella, the French pharmaceutical giant said on Friday.

Sanofi in talks to sell 50% stake in consumer health business to CD&R

Sanofi in discussions to sell a controlling stake in Opella Paris, October 11, 2024 . Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business.

Press Release: Sanofi in discussions to sell a controlling stake in Opella

Private equity firm Clayton Dubilier & Rice (CD&R) is nearing a deal to acquire Sanofi's consumer health unit for about 15 billion euros ($16.4 billion), Bloomberg News reported on Thursday.

CD&R nears deal to buy Sanofi's consumer unit for $16 bln, Bloomberg News reports

Drug developer Denali Therapeutics said on Thursday its partner Sanofi has discontinued a mid-stage study testing their experimental drug to treat multiple sclerosis as it failed to meet the main and secondary goals.

Denali-Sanofi scraps mid-stage study for multiple sclerosis drug

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious Disease Society of America's IDWeek 2024 annual meeting in Los Angeles, California, from October 16-19, 2024.

Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants

AstraZeneca

Bayer AG

Eli Lilly

Pfizer

Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer have been highlighted in this Industry Outlook article.

Zacks Industry Outlook Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer

Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), AstraZeneca (AZN), Pfizer (PFE), Sanofi (SNY) and Bayer (BAYRY) are worth retaining in one's portfolio.

5 Large Drug Stocks to Watch From a Thriving Industry

GlaxoSmithKline

GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, Bloomberg News reported on Friday.

Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply, Bloomberg News reports

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold agglutinin disease (CAD), a rare autoimmune disorder, for $825 million.

Recordati buys rights to rare immune disorder drug from Sanofi for $825 mln

Regeneron Pharmaceuticals

Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Shares of Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) edged higher Friday after their chronic obstructive pulmonary disease (COPD) treatment received approval from the Food and Drug Administration (FDA).

Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD

On Friday, the FDA approved Regeneron Pharmaceuticals, Inc.  REGN and Sanofi SA's SNY Dupixent (dupilumab) as an add-on maintenance treatment of inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype, generally known as “smoker's lung.”

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

Regeneron Pharmaceuticals and Sanofi have won FDA expanded approval of their blockbuster anti-inflammatory drug Dupixent in chronic obstructive pulmonary disease.

News for Sanofi Stock (SNY)